Skip to main content
10/24/2019

Cour Pharmaceuticals Announces Deal with Takeda for Celiac Treatment

Cour Pharmaceuticals has announced a $420 million licensing deal with Takeda Pharmaceuticals following a favorable outcome of their phase 2 trial for celiac disease. The company released data from a small phase 2a study at the annual United European Gastroenterology organization meeting showing that its treatment, CNP-101, cut levels of inflammation-promoting cytokines. The technology was…

Continue Reading
8/6/2019

Bay Area Celiac Disease Study

Researchers are collecting blood samples to learn more about the antigens that cause certain T cells to trigger intestinal damage in celiac disease patients. Complete a 30-minute study from home & be compensated $50 for your time.

Continue Reading
3/27/2019

Celiac Disease Clinical Trial

Attention: Volunteers who have prior confirmation of celiac disease from blood work or a biopsy. If you meet the following criteria, you may qualify for a clinical research study of an investigational drug. Medical insurance is not necessary.

Continue Reading